<DOC>
	<DOCNO>NCT00525447</DOCNO>
	<brief_summary>This Phase I , open-label , multi-dose trial define MTD tolerability regimen include lenalidomide , dexamethasone , intravenous SGN-40 patient relapse multiple myeloma .</brief_summary>
	<brief_title>Study SGN-40 , Lenalidomide , Dexamethasone Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis multiple myeloma . Received least one prior systemic therapy singleagent corticosteroid . Measurable disease monoclonal protein great equal 0.5 gram/dL plasma 0.5 gram/24 hr urine collection , great 10 mg/dL free light chain ( FLC ) serum determine serum FLC assay provide serum FLC ratio abnormal . Received allogenic stem cell transplant . Previous intolerance lenalidomide dexamethasone . Primary invasive malignancy ( multiple myeloma ) within last 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Hemostatic Disorders</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Antibody-Dependent Cell Cytotoxicity</keyword>
</DOC>